Valuation: Design Therapeutics, Inc.

Market Cap 741M 650M 601M 552M 1.04B 71.49B 1.06B 7.18B 2.81B 34.98B 2.78B 2.72B 120B P/E 2026 *
-8.75x
P/E 2027 * -7.23x
Enterprise Value 561M 492M 455M 418M 790M 54.12B 802M 5.44B 2.13B 26.48B 2.11B 2.06B 91.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-5.57%
1 week-21.86%
Current month-17.97%
1 month-4.58%
3 months-9.53%
6 months+27.91%
Current year+26.55%
1 week 11.79
Extreme 11.79
14.83
1 month 11.79
Extreme 11.79
15.86
Current year 8.23
Extreme 8.23
17.25
1 year 3.76
Extreme 3.76
17.25
3 years 1.94
Extreme 1.94
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer 60 2025-04-16
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
6/9/26 Free

Director

30,000 0.0480%
6/9/26 Free

Director

30,000 0.0480%
6/9/26 Free

Director

30,000 0.0480%
Change 5-day change 1-year change 3-year change Capi.($)
-5.57%-21.86%+198.24%+70.79% 785M
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-3.47%+370.99%+567.62% 39.58B
-0.46%+3.98%+5.44%+60.79% 34.69B
-1.14%-1.90%+26.94%-9.56% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-6.91% - - 16.21B
-1.82%-1.91%+69.28%+112.51% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.25%-0.92%+15.77%-32.78% 13.02B
Average -1.90%-1.88%+78.02%+91.15% 24.44B
Weighted average by Cap. -1.45%-0.43%+76.33%+117.48%

Financials

2026 *2027 *
Net sales - -
Net income -85.49M -74.91M -69.27M -63.67M -120M -8.24B -122M -828M -324M -4.03B -321M -314M -13.89B -116M -102M -94.09M -86.48M -163M -11.2B -166M -1.12B -441M -5.48B -436M -426M -18.87B
Net Debt -180M -158M -146M -134M -254M -17.38B -258M -1.75B -684M -8.5B -677M -662M -29.28B -106M -92.97M -85.97M -79.02M -149M -10.23B -152M -1.03B -403M -5.01B -398M -390M -17.24B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
54
Date Price Change Volume
26-07-20 US$11.87 -5.57% 433,762
26-07-17 US$12.57 -0.32% 468,167
26-07-16 US$12.61 -6.73% 900,806
26-07-15 US$13.52 -1.10% 396,307
26-07-14 US$13.67 -1.34% 582,411
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.87USD
Average target price
21.00USD
Spread / Average Target
+76.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock